Myriad Genetics reported Q1 2026 revenue of $200.4 million, up 2% year-over-year, driven by growth in Cancer Care Continuum and Mental Health testing despite a decline in Prenatal Health. The company launched its Precise Molecular Residual Disease (MRD) assay and received FDA approval for the MyChoice CDx test as a companion diagnostic for ovarian cancer treatment. While reporting a GAAP net loss of $34.1 million, Myriad reaffirmed its full-year 2026 revenue guidance of $860-$880 million, expecting stronger second-half performance. The company is advancing new product launches, including an AI-enabled prostate cancer test, positioning for growth in 2027 and beyond.
Shield Therapeutics has agreed to take full commercial control of its oral iron therapy ACCRUFeR in the US from Viatris starting September 30, without any upfront payment. Instead, Shield will pay reduced royalties on US sales over five years. This m...
Autohome reported Q2 2026 results in line with expectations but faces significant challenges due to declining auto sales and reduced dealer advertising budgets in China. Its traditional vertical advertising model is under pressure from alternative pl...
Bread Financial Holdings, formerly Alliance Data, is a U.S. financial services firm specializing in consumer payment and lending solutions. It maintains a strong financial position with a Tier 1 capital ratio near 14% and BB credit ratings, funding i...
BlackRock has purchased over $3.1 billion worth of Bitcoin and Ethereum in just eight days, acquiring 22,722 BTC and 385,633 ETH. This surge in buying coincides with a strong recovery in the broader cryptocurrency market. BlackRock's crypto funds, in...
Marvell Technology reported Q2 earnings and revenue above Wall Street expectations, with data center revenue up 46% year-over-year to $2.17 billion, driven by robust AI-related bookings. Despite this, shares fell 8% in premarket trading as investors ...
